NCT06079411

Virtual Therapeutics for MCI

Low-Cost Virtual Therapeutics and Digital Biomarkers for the Early Assessment and Personalized Treatment of Mild Cognitive Impairment
Istituto Auxologico Italiano·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Mild Cognitive Impairment
Drug/Device/Intervention
virtual reality non-embodied
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Istituto Auxologico Italiano
Location
Milan, Italy
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2023
End date
Jul 01, 2026
Enrollment
36 participants
Primary outcome

The long-term visuospatial memory scores from Corsi supra span,the spatial rotation score from the Manikin Test

Summary

Mild Cognitive Impairment (MCI) is a term used to describe the transitional stage that occurs
 between normal aging and the onset of dementia. Spatial disorientation is often considered a
 significant indicator for diagnosing dementia. Numerous studies have documented deficits in
 both the allocentric and egocentric spatial frames of reference, as well as difficulties in
 transitioning between them, in individuals with MCI. Rapid advances in computing technology
 have enabled researchers to conduct cognitive training and rehabilitation interventions with
 the assistance of technology. Therefore, the aim of the study is to use virtual therapeutics
 to train MCI spatial memory.

ICD-10 classifications
Mild cognitive disorderAlzheimer diseaseDementia in other specified diseases classified elsewhereDementia in other diseases classified elsewhereDementia in Alzheimer disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06079411
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06079411 through Pure Global AI's free database. This phase not specified trial is sponsored by Istituto Auxologico Italiano and is currently Not yet recruiting. The study focuses on Mild Cognitive Impairment. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.